newsfilter
← Latest News
GlobeNewswire·

Conexeu Sciences Launches Human Collagen Initiative for Regenerative Aesthetics as GLP-1 Drives Demand for Tissue Restoration

CNXU
  • Conexeu launched a human collagen initiative at its Vancouver facility to support tissue restoration for aging and significant weight loss, including GLP-1-associated weight loss.
  • The patented CXU™ formula met objectives in the 12-month P.R.O.O.F.™ preclinical study across facial and large-volume models using human collagen from various sources.
  • Conexeu produced its first pilot batch of human type I collagen that met predefined company specifications for identity, structure, protein pattern, & fibril formation.
  • CXU™ is designed as a temporary collagen-based scaffold for structural support & tissue remodeling, differing from conventional dermal fillers used primarily for volumization.
  • The company targets a planned FDA 510(k) submission for the device candidate CXU™ in the first calendar quarter of 2027, subject to successful testing & regulatory documentation.
  • Market analysis indicates the GLP-1 drug market was estimated at $79 billion in 2025 with a projection of $190 billion by 2035, while GLP-1 related aesthetic revenue is projected to grow from $0.7 billion in 2025 to $2.0 billion by 2030.
  • Human collagen is used as the foundation for CXU™, a multi-component scaffold formulation intended to mimic the body's extracellular matrix rather than acting as a single-component filler.
  • The lead device candidate, Ten Minute Tissue™, is a thermosensitive scaffold that transitions from liquid to stable gel at body temperature within approximately ten minutes.
  • Wound care is expected to be the first commercial indication for CXU™ upon FDA clearance, while any product made with human collagen will require separate regulatory review.
  • The CXU™ platform is protected by a multi-jurisdictional patent estate spanning over 40 jurisdictions, including the U.S., EU, Japan, & Australia.
  • Conexeu is a preclinical-stage company with no current FDA clearance for CXU™, & the human collagen described is a development-stage material not yet part of any submitted device.
Company
Conexeu
Keywords
Nasdaq:CNXU, Conexeu, human collagen, GLP-1, dermal filler, aesthetic injectable